| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
22036 |
| Drug |
Atezolizumab |
| Brand |
Tecentriq® |
| Indication |
As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC. |
| Rapid review commissioned |
18/05/2022 |
| Rapid review completed |
02/06/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard-of-care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/07/2022 |
| Pre-submission consultation with Applicant |
04/10/2022 |
| Full submission received from Applicant |
02/12/2022 |
